• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

次黄嘌呤促进肺血管重塑，腺苷脱氨酶是肺动脉高压的治疗靶点。

Hypoxanthine Promotes Pulmonary Vascular Remodeling and Adenosine Deaminase Is a Therapeutic Target for Pulmonary Hypertension.

作者信息

Shi Jun-Zhuo, Zhu Yong-Jian, Zhang Meng-Jie, Yan Yi, Zhao Lu-Ling, Zhang Hong-Da, Liu Yan, Wu Wen-Hui, Cheng Zhe, Qiu Chun-Guang, Kou Jie-Jian, Zhou Yun-Feng, Pang Xiao-Bin, Chen Ji-Wang, Xie Xin-Mei, He Yang-Yang, Jing Zhi-Cheng

机构信息

School of Pharmacy, Henan University, Kaifeng, China; Anesthesiology Department of Huaihe Hospital, Henan University, Kaifeng, China.

Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

出版信息

JACC Basic Transl Sci. 2025 Aug;10(8):101273. doi: 10.1016/j.jacbts.2025.03.005.

DOI:10.1016/j.jacbts.2025.03.005
PMID:40866047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12399150/
Abstract

Uric acid metabolism is implicated in the pathogenesis of pulmonary arterial hypertension, wherein the key metabolite hypoxanthine exhibits elevated levels, thereby promoting pulmonary vascular remodeling through facilitation of cell proliferation and migration as well as regulation of adenosine triphosphate binding cassette transport signaling pathway. Consequently, therapeutic interventions targeting hypoxanthine synthesis may hold promise for the management of pulmonary arterial hypertension.

摘要

尿酸代谢与肺动脉高压的发病机制有关，其中关键代谢产物次黄嘌呤水平升高，从而通过促进细胞增殖和迁移以及调节三磷酸腺苷结合盒转运信号通路来促进肺血管重塑。因此，针对次黄嘌呤合成的治疗干预可能为肺动脉高压的治疗带来希望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/b8287deddaa6/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/e9c9aeedb97d/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/1f368b12f90c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/74cbbea27a42/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/4133f73528c0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/ee3efd271954/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/a6f3ed7ac239/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/49cf5f2ee792/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/3f65585541e2/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/f946be4517f6/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/02e20a67219a/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/a9408648d5a3/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/dd7d2c4873cf/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/b8287deddaa6/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/e9c9aeedb97d/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/1f368b12f90c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/74cbbea27a42/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/4133f73528c0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/ee3efd271954/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/a6f3ed7ac239/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/49cf5f2ee792/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/3f65585541e2/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/f946be4517f6/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/02e20a67219a/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/a9408648d5a3/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/dd7d2c4873cf/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b17/12399150/b8287deddaa6/gr12.jpg

相似文献

1
Hypoxanthine Promotes Pulmonary Vascular Remodeling and Adenosine Deaminase Is a Therapeutic Target for Pulmonary Hypertension.次黄嘌呤促进肺血管重塑，腺苷脱氨酶是肺动脉高压的治疗靶点。
JACC Basic Transl Sci. 2025 Aug;10(8):101273. doi: 10.1016/j.jacbts.2025.03.005.
2
FAP Promotes Pulmonary Artery Hypertension via Activation of the PTEN/PI3K/Akt Pathway.家族性腺瘤性息肉病通过激活PTEN/PI3K/Akt信号通路促进肺动脉高压。
J Cardiovasc Pharmacol. 2025 Jul 17. doi: 10.1097/FJC.0000000000001735.
3
Integrated transcriptome and metabolome analysis reveals the therapeutic mechanism of Huang-Qi-Si-Wu-Tang in experimental pulmonary arterial hypertension.整合转录组和代谢组分析揭示黄芪四物汤对实验性肺动脉高压的治疗机制。
Phytomedicine. 2025 Sep;145:157058. doi: 10.1016/j.phymed.2025.157058. Epub 2025 Jul 7.
4
Mapping disease-specific vascular cell populations responsible for obliterative arterial remodeling during development of pulmonary arterial hypertension.确定在肺动脉高压发展过程中负责闭塞性动脉重塑的疾病特异性血管细胞群。
Cardiovasc Res. 2025 Aug 28. doi: 10.1093/cvr/cvaf146.
5
CircItgb5 promotes synthetic phenotype of pulmonary artery smooth muscle cells via interacting with miR-96-5p and Uba1 in monocrotaline-induced pulmonary arterial hypertension.CircItgb5 通过与 miR-96-5p 和 Uba1 相互作用促进肺动脉平滑肌细胞的合成表型在野百合碱诱导的肺动脉高压。
Respir Res. 2023 Jun 21;24(1):165. doi: 10.1186/s12931-023-02480-9.
6
Mechanism of ferroptosis in hypoxia-induced pulmonary vascular remodeling in hypoxia pulmonary hypertension: a study based on the ACE2-Ang-(1-7)-Mas axis.缺氧性肺动脉高压中缺氧诱导肺血管重塑的铁死亡机制：基于ACE2-Ang-(1-7)-Mas轴的研究
Chem Biol Interact. 2025 Sep 5;418:111596. doi: 10.1016/j.cbi.2025.111596. Epub 2025 Jun 2.
7
Pulmonary vascular fibrosis in pulmonary hypertension - The role of the extracellular matrix as a therapeutic target.肺动脉高压中的肺血管纤维化——细胞外基质作为治疗靶点的作用。
Pharmacol Ther. 2023 Jul;247:108438. doi: 10.1016/j.pharmthera.2023.108438. Epub 2023 May 18.
8
Activated factor X inhibition ameliorates NF-κB-IL-6-mediated perivascular inflammation and pulmonary hypertension.活化因子X抑制可改善NF-κB-IL-6介导的血管周围炎症和肺动脉高压。
Am J Physiol Lung Cell Mol Physiol. 2025 Jul 1;329(1):L183-L196. doi: 10.1152/ajplung.00303.2024. Epub 2025 Jun 13.
9
SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives.SGLT2 抑制剂作为肺动脉高压的一种潜在治疗选择：机制和临床观点。
Crit Rev Clin Lab Sci. 2024 Dec;61(8):709-725. doi: 10.1080/10408363.2024.2361012. Epub 2024 Jun 7.
10
PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension.PDZ 结合激酶：肺动脉高压血管重构的新型调节因子。
Circulation. 2024 Jul 30;150(5):393-410. doi: 10.1161/CIRCULATIONAHA.123.067095. Epub 2024 Apr 29.

引用本文的文献

1
Increased Generation of Hypoxanthine: How Adaptation of Purine Metabolism Drives Vascular Remodeling in Pulmonary Hypertension.次黄嘌呤生成增加：嘌呤代谢的适应性如何驱动肺动脉高压中的血管重塑
JACC Basic Transl Sci. 2025 Aug;10(8):101320. doi: 10.1016/j.jacbts.2025.101320.

本文引用的文献

1
Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer.嘌呤代谢阻断可逆转巨噬细胞免疫抑制并增强非小细胞肺癌的抗肿瘤免疫力。
Drug Resist Updat. 2025 Jan;78:101175. doi: 10.1016/j.drup.2024.101175. Epub 2024 Nov 23.
2
Hyperuricemia and its related diseases: mechanisms and advances in therapy.高尿酸血症及其相关疾病：发病机制与治疗进展。
Signal Transduct Target Ther. 2024 Aug 28;9(1):212. doi: 10.1038/s41392-024-01916-y.
3
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
肺动脉高压的血管反应性阳性检测：现代管理时代的治疗后果、治疗模式和结局。
Circulation. 2024 May 14;149(20):1549-1564. doi: 10.1161/CIRCULATIONAHA.122.063821. Epub 2024 Apr 12.
4
Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas.黄嘌呤磷酸核糖基转移酶 1 将替莫唑胺代谢为激活 AMPK，从而驱动脑胶质瘤的化疗耐药性。
Nat Commun. 2023 Sep 22;14(1):5913. doi: 10.1038/s41467-023-41663-2.
5
Metabolic reprogramming, oxidative stress, and pulmonary hypertension.代谢重编程、氧化应激与肺动脉高压。
Redox Biol. 2023 Aug;64:102797. doi: 10.1016/j.redox.2023.102797. Epub 2023 Jun 24.
6
Single-cell analysis of peripheral blood from high-altitude pulmonary hypertension patients identifies a distinct monocyte phenotype.对高原性肺动脉高压患者外周血的单细胞分析鉴定出一种独特的单核细胞表型。
Nat Commun. 2023 Mar 31;14(1):1820. doi: 10.1038/s41467-023-37527-4.
7
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) drives chronic kidney disease progression in male mice.DNA 依赖性蛋白激酶催化亚基（DNA-PKcs）驱动雄性小鼠慢性肾脏病的进展。
Nat Commun. 2023 Mar 11;14(1):1334. doi: 10.1038/s41467-023-37043-5.
8
Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models.嘌呤合成抑制可减少啮齿动物肺动脉高压模型的发展和进展。
Eur Heart J. 2023 Apr 7;44(14):1265-1279. doi: 10.1093/eurheartj/ehad044.
9
Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism.人脂肪间充质干细胞来源的外泌体通过抑制 PI3K/Akt/mTOR 通路和重塑胆碱代谢来改善肝纤维化。
J Nanobiotechnology. 2023 Jan 25;21(1):29. doi: 10.1186/s12951-023-01788-4.
10
Vascular pathobiology of pulmonary hypertension.肺动脉高压的血管病理生物学。
J Heart Lung Transplant. 2023 May;42(5):544-552. doi: 10.1016/j.healun.2022.12.012. Epub 2022 Dec 21.